Prelude Capital Management’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.17M Buy
35,501
+6,947
+24% +$230K 0.11% 224
2025
Q1
$1.15M Buy
28,554
+8,348
+41% +$336K 0.09% 223
2024
Q4
$950K Buy
20,206
+1,315
+7% +$61.9K 0.06% 325
2024
Q3
$997K Buy
+18,891
New +$997K 0.06% 334
2024
Q2
Sell
-16,023
Closed -$1.12M 1172
2024
Q1
$1.12M Buy
16,023
+4,237
+36% +$297K 0.06% 328
2023
Q4
$984K Buy
11,786
+2,086
+22% +$174K 0.07% 258
2023
Q3
$286K Buy
9,700
+631
+7% +$18.6K 0.02% 582
2023
Q2
$296K Buy
9,069
+1,767
+24% +$57.6K 0.02% 560
2023
Q1
$257K Buy
+7,302
New +$257K 0.02% 644
2020
Q4
Sell
-18,564
Closed -$402K 946
2020
Q3
$402K Buy
18,564
+7,461
+67% +$162K 0.02% 326
2020
Q2
$262K Buy
11,103
+8,634
+350% +$204K 0.01% 433
2020
Q1
$29K Sell
2,469
-5,465
-69% -$64.2K ﹤0.01% 581
2019
Q4
$84K Buy
+7,934
New +$84K ﹤0.01% 795
2019
Q1
Sell
-215
Closed -$1K 1414
2018
Q4
$1K Buy
+215
New +$1K ﹤0.01% 1333
2018
Q2
Sell
-43,743
Closed -$315K 1418
2018
Q1
$315K Sell
43,743
-2,595
-6% -$18.7K 0.02% 504
2017
Q4
$378K Buy
46,338
+10,534
+29% +$85.9K 0.03% 429
2017
Q3
$519K Buy
35,804
+11,322
+46% +$164K 0.05% 323
2017
Q2
$296K Sell
24,482
-387
-2% -$4.68K 0.03% 413
2017
Q1
$320K Buy
24,869
+19,469
+361% +$251K 0.03% 381
2016
Q4
$66K Buy
5,400
+2,500
+86% +$30.6K 0.01% 927
2016
Q3
$27K Buy
2,900
+1,400
+93% +$13K ﹤0.01% 1197
2016
Q2
$14K Buy
+1,500
New +$14K ﹤0.01% 1292
2016
Q1
Sell
-2,800
Closed -$29K 1231
2015
Q4
$29K Sell
2,800
-6,413
-70% -$66.4K ﹤0.01% 1071
2015
Q3
$62K Buy
9,213
+5,063
+122% +$34.1K 0.01% 913
2015
Q2
$28K Sell
4,150
-2,100
-34% -$14.2K ﹤0.01% 1203
2015
Q1
$42K Sell
6,250
-13,000
-68% -$87.4K 0.01% 1334
2014
Q4
$154K Hold
19,250
0.02% 753
2014
Q3
$68K Buy
19,250
+6,700
+53% +$23.7K 0.01% 1175
2014
Q2
$60K Buy
12,550
+10,550
+528% +$50.4K 0.01% 1159
2014
Q1
$19K Sell
2,000
-3,500
-64% -$33.3K ﹤0.01% 1517
2013
Q4
$36K Buy
+5,500
New +$36K 0.01% 1075